Used as a key intermediate in the synthesis of cyclin-dependent kinase (CDK) inhibitors, particularly in the development of anticancer agents. Its structure allows selective modification to enhance binding affinity to CDK enzymes, especially CDK4 and CDK6, which play critical roles in cell cycle regulation. This compound is employed in pharmaceutical research to design targeted therapies for cancers such as breast cancer, leukemia, and melanoma. It is also utilized in structure-activity relationship (SAR) studies to optimize potency, selectivity, and pharmacokinetic properties of drug candidates.